title: Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
abstract: OBJECTIVE
  A recombinant lipoprotein vaccine against Lyme disease, containing 30 microg of Borrelia burgdorferi outer surface protein A (OspA) with aluminum adjuvant, has been shown in a large US field trial of subjects >/=15 years of age to offer 76% efficacy against clinical Lyme disease after 3 injections given at 0, 1, and 12 months. Lyme disease is also an important problem in children; thus, OspA vaccine trials in children are needed. The purpose of this study was to investigate the safety and immunogenicity of 2 different doses of lipoprotein OspA with aluminum adjuvant vaccine in healthy children 5 to 15 years of age in a double-blind, randomized study.
  
  
  METHODS
  In a double-blind study, 250 children from the Czech Republic were randomly assigned to receive 15 microg or 30 microg of OspA vaccine at 0, 1, and 2 months. Serum samples, obtained before vaccination and 1 month after the second and third doses, were analyzed for antiOspA antibody. Solicited and unsolicited symptoms were collected from diary cards.
  
  
  RESULTS
  Local pain at the injection site was reported by approximately 76% of the 250 children. Headaches (after 5% to 18% of the injections) and malaise (after 2% to 16% of the injections) were the most frequently reported general symptoms. Local and generalized symptoms were not different between the 15 microg and 30 microg groups, and all symptoms resolved within 4 days. Both doses were highly immunogenic, with the 30 microg dose eliciting higher antibody levels. Seroconversion occurred in 99% of the 250 children.
  
  
  CONCLUSIONS
  The OspA vaccine against Lyme disease was well tolerated and highly immunogenic in children.
authors.affiliation: Department of Family Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030-1406, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Feder
authors.forename: J
authors.initials: J
authors.lastname: Beran
authors.forename: C
authors.initials: C
authors.lastname: Van Hoecke
authors.forename: B
authors.initials: B
authors.lastname: Abraham
authors.forename: N
authors.initials: N
authors.lastname: De Clercq
authors.forename: C
authors.initials: C
authors.lastname: Buscarino
authors.forename: D L
authors.initials: DL
authors.lastname: Parenti
mesh_terms: D000293:Adolescent; D000818:Animals; D000954:Antigens, Surface / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D008074:Lipoproteins; D008193:Lyme Disease / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D014611:Vaccination
chemical_list: D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein